Control and monitoring of lipoprotein levels in atherosclerosis induced rabbits using novel nanoparticulate medication of Lovastatin and Rosuvastatin
Abstract Different epidemiological studies have demonstrated higher level of uric acid and Lipoprotein levels as risk factors for atherosclerosis. The present investigation deals with formulation of novel combination of Rosuvastatin and Lovastatin in nanoparticulate form to assess atherosclerosis mo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-09-01
|
| Series: | Micro & Nano Letters |
| Online Access: | https://doi.org/10.1049/mna2.12081 |
| _version_ | 1818671527001849856 |
|---|---|
| author | Guoyi Luo Wenjie Chen Jianjun Luo Jie Liu |
| author_facet | Guoyi Luo Wenjie Chen Jianjun Luo Jie Liu |
| author_sort | Guoyi Luo |
| collection | DOAJ |
| description | Abstract Different epidemiological studies have demonstrated higher level of uric acid and Lipoprotein levels as risk factors for atherosclerosis. The present investigation deals with formulation of novel combination of Rosuvastatin and Lovastatin in nanoparticulate form to assess atherosclerosis model. The ionic gelation method was found to be useful for the preparation of chitosan nanoparticles which are evaluated for different parameters like morphology, zeta potential, and polydispersity index found to be satisfactory for delivery of drug. Application of statistical model confirms the effect of Poloxamer 188 and chitosan on drug release and Encapsulation efficiency and drug release. The drug release of Rosuvastatin‐Lovastatin nanoparticles (RST‐LST‐NP) was compared with individual Rosuvastatin nanoparticles (RST‐NP) and Lovastatin nanoparticles (LST‐NP). The results obtained from serum uric acid analysis as well as measurement of level of total cholesterol, high density cholesterol, low density cholesterol shows superiority of RST‐LST‐NP over RST‐NP and LST‐NP in lowering and maintaining serum lipoprotein levels. |
| first_indexed | 2024-12-17T07:25:25Z |
| format | Article |
| id | doaj.art-276108dcea554b618096af4300b0ffb7 |
| institution | Directory Open Access Journal |
| issn | 1750-0443 |
| language | English |
| last_indexed | 2024-12-17T07:25:25Z |
| publishDate | 2021-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Micro & Nano Letters |
| spelling | doaj.art-276108dcea554b618096af4300b0ffb72022-12-21T21:58:38ZengWileyMicro & Nano Letters1750-04432021-09-01161155856510.1049/mna2.12081Control and monitoring of lipoprotein levels in atherosclerosis induced rabbits using novel nanoparticulate medication of Lovastatin and RosuvastatinGuoyi Luo0Wenjie Chen1Jianjun Luo2Jie Liu3Pharmacy department People's Hospital of Chongqing Shuangqiao Economic and Technological Development Zone Chongqing Chongqing ChinaPharmacy department People's Hospital of Chongqing Shuangqiao Economic and Technological Development Zone Chongqing Chongqing ChinaPharmacy department People's Hospital of Chongqing Shuangqiao Economic and Technological Development Zone Chongqing Chongqing ChinaPharmacy department People's Hospital of Chongqing Shuangqiao Economic and Technological Development Zone Chongqing Chongqing ChinaAbstract Different epidemiological studies have demonstrated higher level of uric acid and Lipoprotein levels as risk factors for atherosclerosis. The present investigation deals with formulation of novel combination of Rosuvastatin and Lovastatin in nanoparticulate form to assess atherosclerosis model. The ionic gelation method was found to be useful for the preparation of chitosan nanoparticles which are evaluated for different parameters like morphology, zeta potential, and polydispersity index found to be satisfactory for delivery of drug. Application of statistical model confirms the effect of Poloxamer 188 and chitosan on drug release and Encapsulation efficiency and drug release. The drug release of Rosuvastatin‐Lovastatin nanoparticles (RST‐LST‐NP) was compared with individual Rosuvastatin nanoparticles (RST‐NP) and Lovastatin nanoparticles (LST‐NP). The results obtained from serum uric acid analysis as well as measurement of level of total cholesterol, high density cholesterol, low density cholesterol shows superiority of RST‐LST‐NP over RST‐NP and LST‐NP in lowering and maintaining serum lipoprotein levels.https://doi.org/10.1049/mna2.12081 |
| spellingShingle | Guoyi Luo Wenjie Chen Jianjun Luo Jie Liu Control and monitoring of lipoprotein levels in atherosclerosis induced rabbits using novel nanoparticulate medication of Lovastatin and Rosuvastatin Micro & Nano Letters |
| title | Control and monitoring of lipoprotein levels in atherosclerosis induced rabbits using novel nanoparticulate medication of Lovastatin and Rosuvastatin |
| title_full | Control and monitoring of lipoprotein levels in atherosclerosis induced rabbits using novel nanoparticulate medication of Lovastatin and Rosuvastatin |
| title_fullStr | Control and monitoring of lipoprotein levels in atherosclerosis induced rabbits using novel nanoparticulate medication of Lovastatin and Rosuvastatin |
| title_full_unstemmed | Control and monitoring of lipoprotein levels in atherosclerosis induced rabbits using novel nanoparticulate medication of Lovastatin and Rosuvastatin |
| title_short | Control and monitoring of lipoprotein levels in atherosclerosis induced rabbits using novel nanoparticulate medication of Lovastatin and Rosuvastatin |
| title_sort | control and monitoring of lipoprotein levels in atherosclerosis induced rabbits using novel nanoparticulate medication of lovastatin and rosuvastatin |
| url | https://doi.org/10.1049/mna2.12081 |
| work_keys_str_mv | AT guoyiluo controlandmonitoringoflipoproteinlevelsinatherosclerosisinducedrabbitsusingnovelnanoparticulatemedicationoflovastatinandrosuvastatin AT wenjiechen controlandmonitoringoflipoproteinlevelsinatherosclerosisinducedrabbitsusingnovelnanoparticulatemedicationoflovastatinandrosuvastatin AT jianjunluo controlandmonitoringoflipoproteinlevelsinatherosclerosisinducedrabbitsusingnovelnanoparticulatemedicationoflovastatinandrosuvastatin AT jieliu controlandmonitoringoflipoproteinlevelsinatherosclerosisinducedrabbitsusingnovelnanoparticulatemedicationoflovastatinandrosuvastatin |